| NCT05370521 | A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens | TERMINATED | PHASE2 | 2022-05-15 | 2023-08-31 | 2023-08-03 |
| NCT05128942 | A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children with CAH | TERMINATED | PHASE2 | 2021-12-10 | 2025-01-31 | 2025-01-31 |
| NCT04544410 | A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH | TERMINATED | PHASE2 | 2021-02-22 | 2025-01-31 | 2024-10-31 |
| NCT04457336 | A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH | TERMINATED | PHASE2 | 2020-08-26 | 2024-05-23 | 2024-02-09 |
| NCT03687242 | Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia | COMPLETED | PHASE2 | 2018-09-06 | 2019-08-09 | 2019-07-08 |
| NCT03257462 | Study of SPR001 in Adults with Classic Congenital Adrenal Hyperplasia | COMPLETED | PHASE2 | 2017-07-26 | 2019-05-28 | 2019-04-15 |